Capital One Finl (COF) Holder Hsbc Holdings Plc Lifted Its Position; As Alexion Pharmaceuticals …



July 13, 2018 – By Richard Slagle

Capital One Financial Corporation (NYSE:COF) Logo

Hsbc Holdings Plc increased its stake in Capital One Finl Corp (COF) by 13.64% based on its latest 2018Q1 regulatory filing with the SEC. Hsbc Holdings Plc bought 99,251 shares as the company’s stock declined 5.90% with the market. The institutional investor held 827,057 shares of the major banks company at the end of 2018Q1, valued at $79.25M, up from 727,806 at the end of the previous reported quarter. Hsbc Holdings Plc who had been investing in Capital One Finl Corp for a number of months, seems to be bullish on the $46.08B market cap company. The stock decreased 0.55% or $0.52 during the last trading session, reaching $94.72. About 1.06M shares traded. Capital One Financial Corporation (NYSE:COF) has risen 19.24% since July 13, 2017 and is uptrending. It has outperformed by 6.67% the S&P500. Some Historical COF News: 15/03/2018 – CAPITAL ONE FINANCIAL-30+ DAY PERFORMING DELINQUENCIES RATE FOR DOMESTIC CREDIT CARD 3.92 PCT AT FEB END VS 4.11 PCT AT JAN END; 08/05/2018 – Capital One Had Earlier Sold the Mortgages to Intermediary Credit Suisse; 13/03/2018 – Capital One Closes Below 50-Day Moving Average: Technicals; 09/03/2018 – Fed Says It Will Not Object To Capital One’s Resubmitted Capital Plan — MarketWatch; 24/04/2018 – Capital One Financial Corp. 1Q Rev $6.9B; 24/05/2018 – FACTBOX-Winners and losers from U.S. banking rule rewrite; 24/04/2018 – Capital One 1Q Net Interest Income $5.72 Billion; 09/03/2018 – CAPITAL ONE’S RESUBMITTED CAPITAL PLAN APPROVED BY FED; 24/04/2018 – Capital One 1Q Adj EPS $2.65; 08/05/2018 – Capital One Announces Sale of Approximately $17 billion of Mortgages to DLJ Mortgage Capital, Inc., a subsidiary of Credit Suisse AG

Tobam decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 64.76% based on its latest 2018Q1 regulatory filing with the SEC. Tobam sold 216,282 shares as the company’s stock declined 2.96% with the market. The institutional investor held 117,676 shares of the health care company at the end of 2018Q1, valued at $13.12M, down from 333,958 at the end of the previous reported quarter. Tobam who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $30.28 billion market cap company. The stock increased 1.33% or $1.78 during the last trading session, reaching $136.07. About 790,014 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 19.53% since July 13, 2017 and is uptrending. It has outperformed by 6.96% the S&P500. Some Historical ALXN News: 26/04/2018 – AbbVie Rises on Hepatitis C Beat, Alexion on Study: Health Wrap; 11/04/2018 – From the dawn patrol — Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout $ALXN; 26/04/2018 – ALEXION PHARMACEUTICALS INC – REGULATORY SUBMISSIONS FROM ALXN1210 PHASE 3 PNH NAIVE AND SWITCH STUDIES PLANNED IN U.S. AND EU IN MID-2018; 20/04/2018 – BRAZIL BREAKS PATENT OF ALEXION’S SOLIRIS: ATTORNEY GENERAL; 15/03/2018 – ALEXION PHARMACEUTICALS INC ALXN.O : CREDIT SUISSE RAISES TARGET PRICE TO $149 FROM $147; 11/04/2018 – Alexion: Wilson Therapeutics Board Unanimously Recommends Shareholders Accept the Offer; 11/04/2018 – And now for the top 3 of the day — #1 Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout $ALXN; 15/03/2018 – ALEXION PHARMACEUTICALS – ALXN1210 ALSO ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF LACTATE DEHYDROGENASE NORMALIZATION; 11/04/2018 – Alexion Agrees to Acquire Wilson Therapeutics; 15/03/2018 – Alexion’s second rare blood disorder drug could fortify future revenue

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 25 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Alexion Pharmaceuticals Inc. had 111 analyst reports since July 27, 2015 according to SRatingsIntel. Citigroup maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Friday, February 9. Citigroup has “Buy” rating and $170 target. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by Leerink Swann on Monday, September 26. The rating was upgraded by Morgan Stanley on Thursday, May 25 to “Overweight”. The firm has “Buy” rating given on Thursday, July 27 by Stifel Nicolaus. The rating was maintained by Leerink Swann on Friday, July 28 with “Outperform”. The stock has “Hold” rating by Robert W. Baird on Tuesday, October 24. The firm has “Buy” rating by BMO Capital Markets given on Friday, October 20. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Equal-Weight” rating given on Tuesday, December 13 by Morgan Stanley. The stock has “Buy” rating by Leerink Swann on Monday, September 25. JP Morgan upgraded the stock to “Overweight” rating in Tuesday, September 5 report.

Tobam, which manages about $5.57B and $2.43B US Long portfolio, upped its stake in New York Community Bancorp (NYSE:NYCB) by 23,377 shares to 79,819 shares, valued at $1.04 million in 2018Q1, according to the filing. It also increased its holding in Swift Transportation by 168,672 shares in the quarter, for a total of 249,156 shares, and has risen its stake in Viacom Inc (NASDAQ:VIAB).

Since February 5, 2018, it had 1 insider buy, and 15 insider sales for $3.94 million activity. On Tuesday, February 27 O’Neill Julie sold $194,723 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 1,625 shares. Shares for $173,765 were sold by Franchini Indrani Lall. Shares for $147,865 were sold by Moriarty John B. The insider Goff Brian sold 1,651 shares worth $192,028. Wagner Heidi L also sold $83,305 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. $220,703 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by LAW ANNE-MARIE.

More recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “3 Big Stock Charts for Thursday: Express Scripts Holding Co, Alexion Pharmaceuticals and Ventas” on July 05, 2018. Also Bizjournals.com published the news titled: “Future home of PTC, Alexion could sell for $450M” on June 20, 2018. 247Wallst.com‘s news article titled: “Short Sellers Back Off Major Biotechs” with publication date: July 12, 2018 was also an interesting one.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.03, from 1.03 in 2017Q4. It worsened, as 43 investors sold ALXN shares while 184 reduced holdings. 60 funds opened positions while 167 raised stakes. 200.94 million shares or 1.68% less from 204.38 million shares in 2017Q4 were reported. Honeywell International Inc invested 0.8% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Commerzbank Aktiengesellschaft Fi holds 111,425 shares. The Bermuda-based Fil Limited has invested 0.04% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). De Burlo Gp has 20,096 shares. Everence Mgmt holds 0.11% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 4,295 shares. Tudor Inv Et Al reported 20,202 shares. Icon Advisers has 36,400 shares. Moreover, Pictet Asset Management Ltd has 0.43% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Meiji Yasuda Life Insur reported 5,990 shares or 0.1% of all its holdings. Advsrs Asset Inc holds 14,856 shares. Jbf Cap owns 58,000 shares or 1.02% of their US portfolio. Moreover, California Employees Retirement has 0.08% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Boston Advsrs Limited Liability reported 0.48% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Cubist Systematic Strategies Lc holds 0.04% or 5,879 shares. Comerica Securities has invested 0.06% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on July, 26 before the open. They expect $1.47 EPS, up 12.21% or $0.16 from last year’s $1.31 per share. ALXN’s profit will be $327.08M for 23.14 P/E if the $1.47 EPS becomes a reality. After $1.53 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -3.92% negative EPS growth.

Investors sentiment decreased to 1.01 in Q1 2018. Its down 0.02, from 1.03 in 2017Q4. It turned negative, as 43 investors sold COF shares while 260 reduced holdings. 75 funds opened positions while 230 raised stakes. 418.02 million shares or 2.87% more from 406.36 million shares in 2017Q4 were reported. Bowen Hanes invested in 0.01% or 2,174 shares. E&G Advsrs Ltd Partnership holds 0.13% or 3,044 shares in its portfolio. Andra Ap has 100,500 shares. The California-based California Public Employees Retirement Systems has invested 0.19% in Capital One Financial Corporation (NYSE:COF). Beese Fulmer Inv Management has invested 0.05% in Capital One Financial Corporation (NYSE:COF). Endeavour Inc reported 2.32% in Capital One Financial Corporation (NYSE:COF). Strs Ohio stated it has 0.18% in Capital One Financial Corporation (NYSE:COF). Community Bankshares Na holds 0.01% or 675 shares. Envestnet Asset Mgmt Inc reported 0.02% stake. Triangle Securities Wealth Management reported 9,392 shares or 0.52% of all its holdings. Da Davidson And owns 25,133 shares. Thrivent Finance For Lutherans invested in 0.17% or 537,350 shares. Greenleaf Trust holds 6,314 shares. Missouri-based Duncker Streett Co has invested 0.01% in Capital One Financial Corporation (NYSE:COF). Hermes Inv Mngmt stated it has 0.81% of its portfolio in Capital One Financial Corporation (NYSE:COF).

Hsbc Holdings Plc, which manages about $67.16B US Long portfolio, decreased its stake in Viacom Inc New (Put) (NASDAQ:VIAB) by 251,267 shares to 63,200 shares, valued at $1.96 million in 2018Q1, according to the filing. It also reduced its holding in First Merchants Corp (NASDAQ:FRME) by 57,577 shares in the quarter, leaving it with 4,851 shares, and cut its stake in Nucor Corp (NYSE:NUE).

Among 36 analysts covering Capital One Financial Corp. (NYSE:COF), 23 have Buy rating, 1 Sell and 12 Hold. Therefore 64% are positive. Capital One Financial Corp. had 127 analyst reports since July 24, 2015 according to SRatingsIntel. Nomura upgraded it to “Buy” rating and $105 target in Wednesday, March 29 report. The firm earned “Buy” rating on Thursday, March 29 by Wells Fargo. The stock of Capital One Financial Corporation (NYSE:COF) has “Neutral” rating given on Wednesday, January 13 by DA Davidson. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, April 5. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, June 14 report. The company was upgraded on Wednesday, April 27 by Sandler O’Neill. The firm has “Overweight” rating by Barclays Capital given on Tuesday, January 3. The stock of Capital One Financial Corporation (NYSE:COF) has “Neutral” rating given on Tuesday, October 11 by Wedbush. The firm has “Hold” rating given on Monday, November 14 by Stifel Nicolaus. Compass Point upgraded Capital One Financial Corporation (NYSE:COF) on Friday, December 22 to “Buy” rating.

More notable recent Capital One Financial Corporation (NYSE:COF) news were published by: Streetinsider.com which released: “Synchrony Financial (SYF) in Better Position to Retain Wal-Mart (WMT) Deal – RBC” on July 12, 2018, also 247Wallst.com with their article: “Oppenheimer Positive on Banks Into Earnings: 4 to Buy Now” published on July 13, 2018, Bizjournals.com published: “San Francisco fintech LendUp adds star power to boardroom” on June 21, 2018. More interesting news about Capital One Financial Corporation (NYSE:COF) were released by: Benzinga.com and their article: “Capital One’s Credit Headwinds Are Reversing, Oppenheimer Says In Upgrade” published on July 09, 2018 as well as Seekingalpha.com‘s news article titled: “More bank capital returns: Capital One, Discover, Santander Consumer, State Street” with publication date: June 28, 2018.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.